{
    "root": "d46a2b80-6fff-4b79-a86a-d8b02b5d746a",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "TYSABRI",
    "value": "20250321",
    "ingredients": [
        {
            "name": "natalizumab",
            "code": "3JB47N2Q2P"
        },
        {
            "name": "sodium chloride",
            "code": "451W47IQ8X"
        },
        {
            "name": "sodium phosphate, monobasic, monohydrate",
            "code": "593YOG76RN"
        },
        {
            "name": "sodium phosphate, dibasic, heptahydrate",
            "code": "70WT22SF4B"
        },
        {
            "name": "polysorbate 80",
            "code": "6OZP39ZG8H"
        },
        {
            "name": "water",
            "code": "059QF0KO0R"
        }
    ],
    "indications": "TYSABRI is an integrin receptor antagonist indicated for treatment of: Multiple Sclerosis (MS) TYSABRI is indicated as monotherapy for the treatment of relapsing forms of multiple sclerosis, to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. TYSABRI increases the risk of PML [See Warnings and Precautions ( 5.1 ) ]. When initiating and continuing treatment with TYSABRI, physicians should consider whether the expected benefit of TYSABRI is sufficient to offset this risk. ( 1.1 ) Crohn's Disease (CD) TYSABRI is indicated for inducing and maintaining clinical response and remission in adult patients with moderately to severely active Crohn's disease with evidence of inflammation who have had an inadequate response to, or are unable to tolerate, conventional CD therapies and inhibitors of TNF-α. ( 1.2 ) Important Limitations: In CD, TYSABRI should not be used in combination with immunosuppressants or inhibitors of TNF-α. ( 1.2 )",
    "contraindications": "300 mg infused intravenously over one hour, every four weeks.  Do not give as an intravenous push or bolus ( 2.1 , 2.2 ) TYSABRI solution must be administered within 48 hours of preparation ( 2.3 ) Observe patients during all infusions. Post-infusion, for the first 12 infusions, observe patients for one hour after the infusion is complete. For patients who have received 12 infusions without evidence of a hypersensitivity reaction, observe patients post-infusion for the 13th and subsequent infusions according to clinical judgment. ( 2.4 ) In CD, discontinue in patients that have not experienced therapeutic benefit by 12 weeks of induction therapy, and in patients that cannot discontinue chronic concomitant steroids within six months of starting therapy ( 2.2 )",
    "warningsAndPrecautions": "TYSABRI (natalizumab) injection, a sterile, preservative-free, colorless and clear to slightly opalescent solution for dilution prior to intravenous infusion, is supplied as one 300 mg/15 mL (20 mg/mL) single-dose vial per carton (NDC 64406-008-01).\n\n                  TYSABRI is available only through registered infusion centers participating in the TOUCH® Prescribing Program. To locate these infusion centers, contact Biogen at 1-800-456-2255.\n\n                  TYSABRI single-dose vials must be refrigerated between 2°C to 8°C (36°F to 46°F). Do not use beyond the expiration date stamped on the carton and vial label. DO NOT SHAKE OR FREEZE. Protect from light. \n\n                  Store diluted TYSABRI solution refrigerated at 2°C to 8°C (36°F to 46°F) [see Dosage and Administration (2.3)]",
    "adverseReactions": "TYSABRI is contraindicated in patients who have or have had progressive multifocal leukoencephalopathy (PML) [see Warnings and Precautions (5.1)].\n\n                     TYSABRI is contraindicated in patients who have had a hypersensitivity reaction to TYSABRI. Observed reactions range from urticaria to anaphylaxis [see Warnings and Precautions (5.5)]."
}